Lilly Completes Acquisition of Sigilon Therapeutics | Eli Lilly and Company - Eli Lilly
2023-08-14 • Google News
Sigilon Therapeutics Inc (SGTX)
US$ 3.930%
Price Chart
Key Statistics
Market Cap
$ 56.22M
P/E Ratio
0.00
Revenue (TTM)
$ 17.65M
Volume
10.43K
52W High
$ 0.00
52W Low
$ 0.00
Dividend Yield
0.00%
Beta
4.12
Technicals
50-Day MA
17.3509
200-Day MA
10.359
52 Week High
N/A
52 Week Low
N/A
About SGTX
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases.
Employees
62
Headquarters
Cambridge, MA
CEO
Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA
Latest News
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly - Yahoo Finance
2023-06-30 • Google News
Sigilon Therapeutics (SGTX) Stock Price, News & Analysis - MarketBeat
2020-12-05 • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg